Despite trend toward lower stroke risk with high dose
Your search for dabigatran returned 48 results
The increased number of post-marketing reports of bleeding associated with use of dabigatran seems to be an example of stimulated reporting and may not represent an increased bleeding risk.
A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.
Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
For patients with venous thromboembolism, extended treatment with dabigatran is noninferior to warfarin.
Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding